Sinotherapeutics Inc. (688247.SH) Net profit in 2024 was 128 million yuan, an increase of 109.97% year-on-year.
Xuan Tai Pharmaceutical (688247.SH) released its 2024 annual performance report. During the reporting period, the company achieved a total operating income...
Sinotherapeutics Inc. (688247.SH) releases its performance report for the year 2024. During the reporting period, the company achieved a total operating income of 513 million yuan, a year-on-year increase of 70.97%. Net profit attributable to owners of the parent company was 128 million yuan, up 109.97% year-on-year.
During the reporting period, the company focused on its core business, continuously strengthened domestic and international product sales, and saw significant growth in product sales revenue and equity income. Additionally, as CRO/CMO customer products obtained market approval and commercial production and supply increased, CMO revenue saw significant growth as well.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
